Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Regulatory T-cells (Treg) are essential to Tregs homeostasis and modulate the antitumor immune response in patients with lymphoma. However, the biology and prognostic impact of Tregs in splenic marginal zone lymphoma (SMZL) have not been studied.
Experimental Design: Biopsy specimens from 24 patients with SMZL and 12 reactive spleens (rSP) from individuals without lymphoma were analyzed by using CITE-seq (cellular indexing of transcriptomes and epitopes by sequencing), CyTOF (mass cytometry) analysis, and flow cytometry to explore the phenotype, transcriptomic profile, and clinical significance of intratumoral Tregs and their subsets. The biological characteristics and cell signaling pathways of intratumoral Treg subsets were confirmed by in vitro functional assays.
Results: We found that Tregs are more abundant in SMZL patients' spleens than rSP, and Tregs from patients with SMZL and rSP can be separated into CD161+Treg and CD26+Treg subsets. CD161+Tregs are increased in SMZL but have dysregulated immune function. We found that CD161+Treg and CD26+Tregs have unique gene expression and phenotypic profiles and are differentially correlated with patient outcomes. Specifically, increased CD161+Tregs are significantly associated with a favorable prognosis in patients with SMZL, whereas CD26+Tregs are associated with a poor prognosis. Furthermore, activation of the IL2/STAT5 pathway contributes to the induction of CD26+Tregs and can be reversed by STAT5 inhibition.
Conclusions: IL2/STAT5-mediated expansion of CD26+Tregs contributes to a poor clinical outcome in SMZL and may represent a therapeutic opportunity in this disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443733 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-22-0977 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Splenic marginal zone lymphoma associated with chronic inflammatory demyelinating polyradiculoneuropathy: a case report.
J Med Life
July 2025
Department of Internal Medicine, Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.
Chronic inflammatory demyelinating polyradiculopathy (CIDP) is an acquired immune-mediated neuropathy characterized by progressive or relapsing-remitting proximal and distal weakness. Lymphomas are among various hematological malignancies associated with CIDP. Splenic marginal zone lymphoma (SMZL) is a rare, indolent B-cell non-Hodgkin lymphoma that classically presents with splenomegaly and cytopenia.
View Article and Find Full Text PDFUnusual Clinical Presentation of B-Cell Prolymphocytic Leukemia Cases as Splenic Marginal Zone Lymphoma Effectively Treated With Rituximab Monotherapy.
Anticancer Res
August 2025
Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece.
Background/aim: B-cell prolymphocytic leukemia (B-PLL) is a rare B-cell neoplasm, historically classified as a distinct entity, but recently removed from the World Health Organization (WHO) classification due to its overlap with other B-cell chronic leukemic lymphoproliferative disorders (B-CLD). We describe five cases that met the classical peripheral blood criteria for B-PLL but exhibited clinicopathological features identical to splenic marginal zone lymphoma (SMZL). This study highlights the diagnostic challenges and treatment outcomes of these cases, emphasizing the need for reconsidering their classification.
View Article and Find Full Text PDFSOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma.
Clin Lymphoma Myeloma Leuk
May 2025
Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Department of Molecular and Cellular Pharmacology, University of Miami, Miami, FL. Electronic address:
Marginal zone lymphoma (MZL) is a heterogeneous disease representing 7% to 10% of non-Hodgkin lymphomas (NHL). There are no clear guidelines defining the need for treatment initiation and no standardized therapeutic approach for patients with MZL. Previously, many treatments were extrapolated from clinical trials that mainly enrolled patients with follicular lymphoma and did not have statistical power to show treatment efficacy specifically in MZL patients.
View Article and Find Full Text PDFMarginal B-cell lymphoma: A 10-year retrospective study at national institute of hematology and blood transfusion, Vietnam.
SAGE Open Med
April 2025
Gastroenterology and Hepatology Center, Bach Mai Hospital, Hanoi City, Vietnam.
Objective: The prognostic factors of patients diagnosed with marginal zone B-cell lymphoma at the National Institute of Hematology and Blood Transfusion between January 2014 and January 2024 were analyzed.
Subjects And Methods: This cross-sectional descriptive study included 86 newly diagnosed and treated marginal zone B-cell lymphoma patients. Myelogram, histopathology, and immunohistochemical staining were performed for all patients.
Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study.
Hematol Oncol
May 2025
Division of Hematology, Department of Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Given the paucity of age-specific data about biology, presentation, and treatment outcomes in adults with MZL, we sought to evaluate differences between younger (≤ 70 years) and older (> 70 years) patients with MZL in a large retrospective cohort treated in the contemporary era (2010 onwards). The primary objective was progression-free survival (PFS), while secondary objectives included the evaluation of overall survival (OS) and the cumulative incidence of transformation between the 2 groups. A total of 598 patients were included in the analysis and among these 32% were > 70 years of age.
View Article and Find Full Text PDF